Replimune Group, Inc. (NASDAQ:REPL) Stock Holdings Lifted by Jump Financial LLC

Jump Financial LLC grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 95.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,443 shares of the company's stock after buying an additional 34,907 shares during the period. Jump Financial LLC owned about 0.10% of Replimune Group worth $865,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Sterling Capital Management LLC increased its stake in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its holdings in shares of Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the period. XTX Topco Ltd bought a new stake in shares of Replimune Group during the 4th quarter valued at about $137,000. Sei Investments Co. acquired a new stake in Replimune Group during the fourth quarter worth about $148,000. Finally, KLP Kapitalforvaltning AS bought a new position in Replimune Group in the fourth quarter worth about $150,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on REPL. BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $19.43.

Replimune Group Price Performance

REPL stock traded down $0.01 during trading hours on Friday, hitting $9.05. 362,638 shares of the stock traded hands, compared to its average volume of 866,293. The stock has a 50-day simple moving average of $10.34 and a 200 day simple moving average of $11.68. The company has a market cap of $696.99 million, a P/E ratio of -2.95 and a beta of 1.26. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.